Case number IPR2018-00231
Pfizer, Inc. v. Biogen, Inc. > Documents
| Date Field | Doc. No. | Party | Description |
|---|---|---|---|
| Mar 19, 2018 | 2024 | Ex. 2024 Declaration of Sharon Song Download | |
| Mar 19, 2018 | 2023 | Ex. 2023 Definition of Myelosuppression ¿¿¿ NCI Dictionary of Cancer Terms Download | |
| Mar 19, 2018 | 2022 | Ex. 2022 Bio Report Download | |
| Mar 19, 2018 | 2021 | Ex. 2021 NCI 1999 Common Toxicity Criteria Download | |
| Mar 19, 2018 | 2020 | Ex. 2020 Ford & Donegan 1998 Download | |
| Mar 19, 2018 | 2019 | Ex. 2019 Lee 1996 Download | |
| Mar 19, 2018 | 2018 | Ex. 2018 Feenstra 1999 Download | |
| Mar 19, 2018 | 2017 | Ex. 2017 G Goss 1993 Download | |
| Mar 19, 2018 | 2016 | Ex. 2016 Khaled 1999 Download | |
| Mar 19, 2018 | 2015 | Ex. 2015 Solimando 1984 Download | |
| Mar 19, 2018 | 2014 | Ex. 2014 Hashimoto Download | |
| Mar 19, 2018 | 2013 | Ex. 2013 Dallegri Download | |
| Mar 19, 2018 | 2012 | Ex. 2012 Gordon 1992 Download | |
| Mar 19, 2018 | 2011 | Ex. 2011 Bezwoda 1995 Download | |
| Mar 19, 2018 | 2010 | Ex. 2010 Kresina 1998 Download | |
| Mar 19, 2018 | 2009 | Ex. 2009 Czuczman 2004 Download | |
| Mar 19, 2018 | 2008 | Ex. 2008 IPR2018-00186 Petition Download | |
| Mar 19, 2018 | 2007 | Ex. 2007 Czuczman Abstract IDEC-C2B8 and Chop Chemoimmunotherapy of Low-Grade Lymphoma Download | |
| Mar 19, 2018 | 2006 | Ex. 2006 McLaughlin December 1998 Download | |
| Mar 19, 2018 | 2005 | Ex. 2005 E. Philip 1987 Download | |
| Mar 19, 2018 | 2004 | Ex. 2004 PDR 1998 Download | |
| Mar 19, 2018 | 2003 | Ex. 2003 Armitage 1993 Download | |
| Mar 19, 2018 | 2002 | Ex. 2002 K Ozer Deposition Transcript Corrected Download | |
| Mar 19, 2018 | 2001 | Ex. 2001 Czuczman 1999 Download | |
| Dec 1, 2017 | 1036 | Ex. 1036 - Bennett et al., "Cancer Insurance Policies in Japan and the United States," W. J. Med, 168(1):17-22 (1998) Download | |
| Dec 1, 2017 | 1035 | Ex. 1035 - Houts et al., "Nonmedical Costs to Patients and Their Families Associated with Outpatient Chemotherapy," Cancer, 53:2388-2392 (1984) Download | |
| Dec 1, 2017 | 1034 | Ex. 1034 - Rituxan (rituximab) labeling (rev. 2014) Download | |
| Dec 1, 2017 | 1033 | Ex. 1033 - Demidem et al., "Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs," Cancer Biotherapy & Radiopharmaceuticals, 12(3):177-186 (1997) Download | |
| Dec 1, 2017 | 1032 | Ex. 1032 - Grossbard et al., "Monoclonal Antibody-Based Therapies of Leukemia and Lymphoma," Blood, 80(4):863-878 (1992) Download | |
| Dec 1, 2017 | 1031 | Ex. 1031 - McLaughlin et al., "Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program," J. Clinical Oncology, 16(8):2825-2833 (1998) Download | |
| Dec 1, 2017 | 1030 | Ex. 1030 - Michael J. Campbell & John E. Niederhuber, "B-Lymphocyte Responses," Clinical Oncology, Abeloff et al., Eds. (1995), 100-126 Download | |
| Dec 1, 2017 | 1029 | Ex. 1029 - U.S. Application No. 14/310,167, Notice of Allowance (dated October 7, 2016) Download | |
| Dec 1, 2017 | 1028 | Ex. 1028 - U.S. Application No. 14/310,167, Amendment and Response (dated August 2, 2016) Download | |
| Dec 1, 2017 | 1027 | Ex. 1027 - U.S. Application No. 14/310,167, Final Rejection (dated June 23, 2016) Download | |
| Dec 1, 2017 | 1026 | Ex. 1026 - U.S. Application No. 14/310,167, Amendment and Response (dated March 10, 2016) Download | |
| Dec 1, 2017 | 1025 | Ex. 1025 - U.S. Application No. 14/310,167, Non-Final Office Action (dated September 11, 2015) Download | |
| Dec 1, 2017 | 1024 | Ex. 1024 - U.S. Application No. 14/310,167, Utility Patent Application Transmittal claim 1 (dated June 20, 2014) Download | |
| Dec 1, 2017 | 1023 | Ex. 1023 - Declaration of Scott Bennett, Ph.D.- Part 2 Download | |
| Dec 1, 2017 | 1023 | Ex. 1023 - Declaration of Scott Bennett, Ph.D.- Part 3 Download | |
| Dec 1, 2017 | 1023 | Ex. 1023 - Declaration of Scott Bennett, Ph.D.- Part 1 Download | |
| Dec 1, 2017 | 1023 | Ex. 1023 - Declaration of Scott Bennett, Ph.D.- Part 1 Download | |
| Dec 1, 2017 | 1023 | Ex. 1023 - Declaration of Scott Bennett, Ph.D.- Part 1 Download | |
| Dec 1, 2017 | 1022 | Ex. 1022 - Institution of Inter Partes Review, Pfizer, Inc. v. Biogen, Inc., IPR2017-01168 (U.S. Patent No. 8,821,873) Paper 6 (PTAB) Download | |
| Dec 1, 2017 | 1021 | Ex. 1021 - Decision denying Institution of Inter Partes Review, Pfizer, Inc. v. Biogen, Inc., IPR2017-01167 (U.S. Patent No. 8,557,244) Paper 8 (PTAB) Download | |
| Dec 1, 2017 | 1020 | Ex. 1020 - Meyer et al., "A Phase I Trial of Standard and Cyclophosphamide Dose-Esclated CHOP with Granulocyte Colony Stimulating Factor in Elderly Patients with Non-Hodgkin's Lymphoma," Leukemia & Lymphoma, 30:591-600 (1997) Download | |
| Dec 1, 2017 | 1019 | Ex. 1019 - Tsai et al., "Progressive Intermediate Grade Non-Hodgkin's Lymphoma After High Dose Therapy and Autologous Peripheral Stem Cell Transplantation (PSCT) Has a High Response Rate to Rituximab," Blood, 92(10 Suppl. 1):415a (1998) Download | |
| Dec 1, 2017 | 1018 | Ex. 1018 - Physicians' Desk Reference (53rd ed. 1999) (excerpted), "Rituxan (Rituximab)" ("PDR label") Download | |
| Dec 1, 2017 | 1017 | Ex. 1017 - Rituxan (rituximab) labeling (Nov. 1997) ("FDA label") Download | |
| Dec 1, 2017 | 1016 | Ex. 1016 - Martinelli et al., "Development of an Active CHOP-Modified Regimen which Allows more Continuous and Well Tolerated Treatment in Elderly Patients with Aggressive Non-Hodgkin's Lymphomas (NHL)," Ann. Oncology, 7(suppl. 3):60 (1996) Download | |
| Dec 1, 2017 | 1015 | Ex. 1015 - Thomas P. Miller and Stephen E. Jones, "Initial Chemotherapy for Clinically Localized Lymphomas of Unfavorable Histology," Blood, 62(2):413-418 (1983) Download | |
| Dec 1, 2017 | 1014 | Ex. 1014 - Kenneth A. Foon & Richard I. Fisher, "Lymphomas" in Williams Hematology 5th Ed. (Ernest Beutler et al., eds.) 1076-1096 (1995) Download | |
| Dec 1, 2017 | 1013 | Ex. 1013 - Martelli et al., "Current Guidelines for the Management of Aggressive Non-Hodgkin's Lymphoma," Drugs, 53(6):957-972 (1997) Download | |
| Dec 1, 2017 | 1012 | Ex. 1012 - Hiddemann et al. "Lymphoma Classification-The Gap Between Biology and Clinical Management is Closing," Blood, 88(11):4085-4089 (1996) Download | |
| Dec 1, 2017 | 1011 | Ex. 1011 - W. Hiddemann, "Non-Hodgkin's Lymphoma-Current Status of Therapy and Future Perspectives, Eur. J. Cancer, 31A:2141-2145 (1995) Download | |
| Dec 1, 2017 | 1010 | Ex. 1010 - Arthur T. Skarin & David M. Dorfman, "Non-Hodgkin's Lymphomas: Current Classification and Management," CA Cancer J. Clinicians, 47(6):351-372 (1997) Download | |
| Dec 1, 2017 | 1009 | Ex. 1009 - Maloney et al., "IDEC-C2B8: Results of a Phase I Multiple-Dose Trial in Patients with Relapsed Non-Hodgkin's Lymphoma," J. Clinical Oncology, 15(10):3266-3274 (Oct. 1997) Download | |
| Dec 1, 2017 | 1008 | Ex. 1008 - James O. Armitage et al., "Bone Marrow Transplantation," in Clinical Oncology, Abeloff et al., Eds. (1995), 295-305 Download | |
| Dec 1, 2017 | 1007 | Ex. 1007 - Coiffier et al., "Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients with Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study," Blood, 92(6):1927-1932 (1998) Download | |
| Dec 1, 2017 | 1006 | Ex. 1006 - Caroline McNeil, "Non-Hodgkin's Lymphoma Trials In Elderly Look Beyond CHOP," J. Nat'l Cancer Inst., 90(4):266-67 (Feb. 18, 1998) Download | |
| Dec 1, 2017 | 1005 | Ex. 1005 - Link et al., "Phase II Pilot Study of the Safety and Efficacy of Rituximab in Combination with CHOP Chemotherapy in Patients with Previously Untreated Intermediate-or High-Grade NHL," ASCO, Program/Proceedings, 34th Annual Meeting, (May 1998) Download | |
| Dec 1, 2017 | 1004 | Ex. 1004 - Meyer et al., "Randomized Phase II Comparison of Standard CHOP with Weekly CHOP in Elderly Patients with Non-Hodgkin's Lymphoma," J. Clin. Oncol. 13(9):2386-2393 (1995) Download | |
| Dec 1, 2017 | 1003 | Ex. 1003 - Macedo et al., "Standard CHOP with Reduced Dose of Doxorrubicin (mini-CHOP) for Elderly Patients with Intermediate and High Grande Non-Hodgkin's Lymphoma (NHL)," Blood, 84(10 Suppl. 1):644a (1994) Download | |
| Dec 1, 2017 | 1002 | Ex. 1002 - Declaration of Howard Ozer, M.D., Ph.D. Download | |
| Dec 1, 2017 | 1001 | Ex. 1001 - Christine A. White and Antonio J. Grillo-Lopez, U.S. Patent No. 9,504,744 B2 Download | |
| Jun 21, 2018 | 13 | Notice of Refund Download | |
| Jun 8, 2018 | 12 | Petitioner's Motion for Refund of Post-Institution Fee Download | |
| Jun 6, 2018 | 11 | Judgment - 37 C.F.R. 42.5(a); 37 C.F.R. 42.71(a) Download | |
| Jun 4, 2018 | 10 | Petitioner's Authorized Unopposed Motion To Terminate Proceeding With Prejudice Download | |
| Mar 19, 2018 | 9 | Patent Owner Preliminary Response Download | |
| Mar 19, 2018 | 8 | Patent Owner's Exhibit List Download | |
| Jan 31, 2018 | 7 | Petitioner's Updated Mandatory Notice Download | |
| Dec 27, 2017 | 6 | Patent Owner's Updated Mandatory Notice Download | |
| Dec 21, 2017 | 5 | Patent Owner's Mandatory Notice Download | |
| Dec 21, 2017 | 4 | Power of Attorney Download | |
| Dec 18, 2017 | 3 | Notice of Accord Filing Date Download | |
| Dec 1, 2017 | 2 | PETITION FOR INTER PARTES REVIEW (NHL '744) Download | |
| Dec 1, 2017 | 1 | Petitioner's Power of Attorney Download |
